Drug repurposing has emerged as an enigmatic clinical approach in disorders affecting the cardiovascular system. The concept of drug repurposing has become feasible due to an interim in performing trials for new entities in cardiovascular diseases (CVDs) rather than cancer and diabetes. One of the naïve pathologies brought to the forefront was IL-33/ST2. After delving deeply into this pathway, mitigated levels of sST2 (a decoy receptor for IL-33) were found to prevent plaque formation and fibrosis. This novelty demands the identification of novel therapeutic targets. In this study, the chronopharmacology of frequently prescribed conventional cardiovascular medications was evaluated, and a hypothesis on β-blockers and mineralocorticoid receptor antagonists in modulating the IL-33/ST2 pathway was proposed for their ability to upregulate IL-33, which specifically exhibits cardioprotective activity. This future perspective advocates precise influences in aiming for IL-33 as a key factor for repurposing these medications in CVDs that reduce inflammation and help to unravel potential cardioprotective action and promising outcomes.

药物再利用已成为治疗影响心血管系统疾病的一种神秘的临床方法。由于对心血管疾病（CVD）而不是癌症和糖尿病的新实体进行试验的中期，药物再利用的概念已变得可行。 IL-33/ST2 是最受关注的幼稚病理学之一。深入研究这一途径后，发现降低 sST2（IL-33 的诱饵受体）水平可以防止斑块形成和纤维化。这种新颖性需要确定新的治疗靶点。在这项研究中，评估了常用的传统心血管药物的时间药理学，并提出了β受体阻滞剂和盐皮质激素受体拮抗剂在调节IL-33/ST2途径中的假设，因为它们能够上调IL-33，特别表现出心脏保护作用。活动。这种未来的观点主张对 IL-33 进行精确影响，将其作为在 CVD 中重新利用这些药物的关键因素，从而减少炎症并有助于揭示潜在的心脏保护作用和有希望的结果。